drugset / Trial / NCT06357910

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

NCT06357910

Phase 1 Completed 34 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fed condition in healthy volunteers.

Timeline

Start
2024-05-17
Primary completion
2024-07-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP2303 Unknown
Subject RLD2102 Unknown
Subject RLD2302 Unknown

Indications

No indication recorded.